CalciMedica, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $9.1M
- Price
- $0.5765
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.15%
- Volume
- 54.8K
About
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Quick stats
Shares outstanding15.8M
Computed float5.7M
Float / shares36.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001534133
Websitehttps://www.calcimedica.com
AI Summary
AI-generated1/5
majorbullishearnings
CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
CalciMedica reported financial results for Q2 2026, highlighting a recently closed private placement of up to $49 million in gross proceeds, including $15 million upfront, which extends the cash runway into the second half of 2027.
The company received FDA alignment on the primary endpoint for its Phase 2b acute pancreatitis trial, focusing on reducing new-onset severe respiratory failure, with data for the Auxora PAH Phase 1b trial and CM5480 IND submission expected in mid-2027.
Q2 net loss was $7.7 million, or $0.45 per share, compared to a net loss of $6.0 million in the prior year, while R&D and G&A expenses both decreased year-over-year due to reduced clinical and consulting activities.
Red flags
- Initiation of the acute pancreatitis Phase 2b trial is subject to additional financing
- Q2 2026 net loss widened to $7.7 million from $6.0 million in the prior year